Ningbo Menovo Pharmaceutical Co., Ltd.
Symbol: 603538.SS
SHH
14.58
CNYTržní cena dnes
-165.8310
Poměr P/E
-26.5330
Poměr PEG
3.09B
MRK Cap
- 0.01%
Výnos DIV
Ningbo Menovo Pharmaceutical Co., Ltd. (603538-SS) finanční výkazy
Rozvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 724.7 | 1009.3 | 793.2 | |||||||||||||
balance-sheet.row.short-term-investments | 0 | 268.6 | 217.4 | 371.4 | |||||||||||||
balance-sheet.row.net-receivables | 0 | 320.7 | 231.5 | 266.2 | |||||||||||||
balance-sheet.row.inventory | 0 | 612.6 | 594.4 | 579.7 | |||||||||||||
balance-sheet.row.other-current-assets | 0 | 50.3 | 59.2 | 63.4 | |||||||||||||
balance-sheet.row.total-current-assets | 0 | 1759.4 | 1894.4 | 1702.4 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 1900.3 | 1801.9 | 1614.7 | |||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 22.7 | |||||||||||||
balance-sheet.row.intangible-assets | 0 | 206.2 | 172.5 | 201.7 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 206.2 | 172.5 | 224.4 | |||||||||||||
balance-sheet.row.long-term-investments | 0 | 315.3 | 82.7 | -51.8 | |||||||||||||
balance-sheet.row.tax-assets | 0 | 42.7 | 123.1 | 33.3 | |||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 199.6 | 344.8 | 478.5 | |||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 2664.1 | 2525.1 | 2299.1 | |||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 0 | 4423.5 | 4419.5 | 4001.5 | |||||||||||||
balance-sheet.row.account-payables | 0 | 553.7 | 499.3 | 389.1 | |||||||||||||
balance-sheet.row.short-term-debt | 0 | 542.8 | 497 | 505 | |||||||||||||
balance-sheet.row.tax-payables | 0 | 25.5 | 72.1 | 34.6 | |||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 759.6 | 705.6 | 755.3 | |||||||||||||
Deferred Revenue Non Current | 0 | 81.5 | 70.6 | 48.7 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 0 | 2 | 171 | 3.9 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 859.6 | 884 | 876.2 | |||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 15.7 | 30.3 | 28 | |||||||||||||
balance-sheet.row.total-liab | 0 | 2237.8 | 2246.2 | 2023 | |||||||||||||
balance-sheet.row.preferred-stock | 0 | 36.3 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 0 | 213.4 | 213.4 | 151.3 | |||||||||||||
balance-sheet.row.retained-earnings | 0 | 1210.6 | 1234.3 | 937.4 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 75.6 | 101.4 | 77.6 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 560.4 | 535.9 | 585.2 | |||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 2096.3 | 2085 | 1751.5 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 4423.5 | 4419.5 | 4001.5 | |||||||||||||
balance-sheet.row.minority-interest | 0 | 89.4 | 88.3 | 227 | |||||||||||||
balance-sheet.row.total-equity | 0 | 2185.7 | 2173.2 | 1978.5 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||
Total Investments | 0 | 315.3 | 300.1 | 319.6 | |||||||||||||
balance-sheet.row.total-debt | 0 | 1302.5 | 1202.6 | 1260.4 | |||||||||||||
balance-sheet.row.net-debt | 0 | 846.4 | 410.7 | 838.6 |
Výkaz peněžních toků
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 367.6 | 158.1 | 173.1 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 101.8 | 98.9 | 85 | ||||||||||||
cash-flows.row.deferred-income-tax | 0 | -40.2 | -21 | 18.4 | ||||||||||||
cash-flows.row.stock-based-compensation | 0 | 24.7 | 5.3 | 10.9 | ||||||||||||
cash-flows.row.change-in-working-capital | 0 | -85.4 | -62.2 | -2.8 | ||||||||||||
cash-flows.row.account-receivables | 0 | -213.6 | -50.9 | -28.2 | ||||||||||||
cash-flows.row.inventory | 0 | -183 | -124.7 | -83 | ||||||||||||
cash-flows.row.account-payables | 0 | 351.4 | 134.4 | 63.3 | ||||||||||||
cash-flows.row.other-working-capital | 0 | -40.2 | -21 | 45.1 | ||||||||||||
cash-flows.row.other-non-cash-items | 0 | -91.4 | 41.5 | -32.9 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -571.6 | -529.9 | -311.7 | ||||||||||||
cash-flows.row.acquisitions-net | 0 | 487.9 | -47.1 | 0.5 | ||||||||||||
cash-flows.row.purchases-of-investments | 0 | -713.9 | -1640.5 | -865 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 902.5 | 1562.2 | 693.5 | ||||||||||||
cash-flows.row.other-investing-activites | 0 | -54.6 | 52 | 3.8 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 50.3 | -603.3 | -479 | ||||||||||||
cash-flows.row.debt-repayment | 0 | -749.5 | -788.1 | -802.5 | ||||||||||||
cash-flows.row.common-stock-issued | 0 | 0.1 | 0.2 | 0.5 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -0.1 | -0.2 | -0.5 | ||||||||||||
cash-flows.row.dividends-paid | 0 | -50 | -13.8 | -41 | ||||||||||||
cash-flows.row.other-financing-activites | 0 | 621.1 | 1385.1 | 981.9 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -178.5 | 583.1 | 138.4 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 14.6 | -2.3 | -2 | ||||||||||||
cash-flows.row.net-change-in-cash | 0 | 163.4 | 198.2 | -91 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 537 | 373.6 | 174.5 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 373.6 | 175.4 | 265.5 | ||||||||||||
cash-flows.row.operating-cash-flow | 0 | 277 | 220.6 | 251.6 | ||||||||||||
cash-flows.row.capital-expenditure | 0 | -571.6 | -529.9 | -311.7 | ||||||||||||
cash-flows.row.free-cash-flow | 0 | -294.7 | -309.3 | -60.1 |
Řádek výkazu zisku a ztráty
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1216.5 | 1457 | 1258.1 | |||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 840.9 | 872.8 | 788.9 | |||||||||||||
income-statement-row.row.gross-profit | 0 | 375.6 | 584.2 | 469.2 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | 0 | -10.8 | 116.4 | 110.8 | |||||||||||||
income-statement-row.row.operating-expenses | 0 | 291.2 | 341.4 | 281 | |||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1132.1 | 1214.2 | 1069.9 | |||||||||||||
income-statement-row.row.interest-income | 0 | 5.5 | 5.7 | 2.2 | |||||||||||||
income-statement-row.row.interest-expense | 0 | 29.1 | 27.4 | 27.2 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -76.4 | -21.2 | -7.6 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -10.8 | 116.4 | 110.8 | |||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -76.4 | -21.2 | -7.6 | |||||||||||||
income-statement-row.row.interest-expense | 0 | 29.1 | 27.4 | 27.2 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 118.5 | 128.3 | 124.1 | |||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | 0 | 18.7 | 405.3 | 187.9 | |||||||||||||
income-statement-row.row.income-before-tax | 0 | 8 | 384.2 | 180.3 | |||||||||||||
income-statement-row.row.income-tax-expense | 0 | -8.2 | 16.5 | 22.2 | |||||||||||||
income-statement-row.row.net-income | 0 | 11.6 | 338.9 | 142.5 |
Často kladené otázky
Co je Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) celková aktiva?
Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) celková aktiva jsou 4423515920.000.
Jaký je roční obrat podniku?
Roční příjmy jsou N/A.
Jaké je ziskové rozpětí podniku?
Zisková marže firmy je 0.319.
Jaký je volný peněžní tok podniku?
Volný peněžní tok je -0.853.
Jaká je čistá zisková marže podniku?
Čistá zisková marže je -0.014.
Jaké jsou celkové tržby podniku?
Celkové příjmy jsou -0.013.
Co je Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) čistý zisk (čistý příjem)?
Čistý zisk (čistý příjem) je 11585592.000.
Jaký je celkový dluh podniku?
Celkový dluh je 1302458461.000.
Jaké je číslo provozních nákladů?
Provozní výdaje jsou 291175048.000.
Jaké je číslo peněžních prostředků firmy?
Peněžní prostředky podniku jsou 0.000.